EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Efectividad temprana de anifrolumab en lupus eritematoso sistémico: datos de vida real a 3 y 6 meses del registro RALESA

María Dolores Manjón Rodríguez, Isabel Sánchez Berna, Francisco José García Hernández, Francisco Javier de la Hera Fernández, Iván Pérez de Pedro, Alba Gil Morillas, Nuria Navarrete Navarrete, José Luis Callejas Rubio, María Del Mar Ayala Gutiérrez, Carlos Romero Gómez, Laura León Ruíz, Gema Gómiz Rodríguez und 3 weitere

Medicina Clínica · 2026-06 · 166 (6) · 107429

DOI: 10.1016/j.medcli.2026.107429 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medicina Clínica, 2026-06. Verfasst von María Dolores Manjón Rodríguez und 14 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Gestión Clínica Autoinmunes y Minoritarias, Hospital Universitario de Jaén, Jaén, España. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES Systemic lupus erythematosus (SLE) is an autoimmune disease with numerous immune defects described. Anifrolumab (ANF) is an effective and safe biologic drug approved for SLE after completion of a rigorous clinical development program. By building on the experience gained in clinical practice, it is possible to expand the knowledge of real-world benefits. The aim of the study is to study the efficacy and safety of ANF in real life. METHODS Observational study conducted in hospitals in the autonomous community of Andalusia on the early efectiveness and safety of ANF treatment in 56 patients with SLE. Indicators of activity and chronicity were determined at baseline and at 3 and 6 months. RESULTS The main clinical domains were mucocutaneous (80.4%) and osteoarticular (37.5%). At 3 and 6 months, response rates were SRI-4: 48% and 66%, BICLA: 57% and 77%, CLASI-A50: 85% and 93%, LLDAS: 71% and 66%, and DORIS remission, 36% and 43%, respectively. There was a decrease in mean daily prednisone dose after ANF initiation, with 76.8% and 80.3% of patients at a dose ≤ 7.5mg/day at 3 and 6 months respectively. No significant adverse effects were observed. CONCLUSIONS In SLE, especially in patients with mucocutaneous and joint involvement, ANF is an effectiveness and safe therapeutic option in real clinical practice, with improvement of activity markers at 3 and 6 months of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntibodies, Monoclonal, HumanizedHumansFemaleMaleTreatment OutcomeAdultRegistriesMiddle AgedYoung AdultTime FactorsRemission Induction

Stichwörter der Autor:innen

AnifrolumabEstudio de vida realLupus eritematoso sistémicoReal world studySystemic lupus erythematosus

Substanzen

Antibodies, Monoclonal, Humanizedanifrolumab

Autor:innen und Institutionen

  • Unidad de Gestión Clínica Autoinmunes y Minoritarias, Hospital Universitario de Jaén, Jaén, España.
  • Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, MP03-Medicina Interna-HVN Investiga, Instituto de Investigación Biosanitaria IBS Granada, Granada…
  • Servicio de Medicina Interna, Hospital Virgen del Rocío, Sevilla, España.
  • Unidad de Enfermedades Sistémicas, Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria IBS Granada, Granada, España.
  • Unidad de Enfermedades Sistémicas, Hospital Regional Universitario de Málaga, Málaga, España.
  • Unidad de Enfermedades Sistémicas, Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria IBS Granada, Granada, España. Electronic address: jlcalleja@telefonica.net.

Zitieren

APA

Manjón Rodríguez, M. D., Sánchez Berna, I., García Hernández, F. J., de la Hera Fernández, F. J., Pérez de Pedro, I., Gil Morillas, A., Navarrete Navarrete, N., Callejas Rubio, J. L., Ayala Gutiérrez, M. D. M., Romero Gómez, C., León Ruíz, L., Gómiz Rodríguez, G., Borrachero Garro, C., Vílchez Parras, A., & Colodro Ruiz, A. (2026). Efectividad temprana de anifrolumab en lupus eritematoso sistémico: datos de vida real a 3 y 6 meses del registro RALESA. Medicina Clínica, 166(6), 107429. https://doi.org/10.1016/j.medcli.2026.107429

Vancouver

Manjón Rodríguez MD, Sánchez Berna I, García Hernández FJ, de la Hera Fernández FJ, Pérez de Pedro I, Gil Morillas A, et al. Efectividad temprana de anifrolumab en lupus eritematoso sistémico: datos de vida real a 3 y 6 meses del registro RALESA. Medicina Clínica. 2026;166(6):107429. doi:10.1016/j.medcli.2026.107429

BibTeX
@article{ManjnRodrguez2026,
  author = {Manjón Rodríguez, María Dolores and Sánchez Berna, Isabel and García Hernández, Francisco José and de la Hera Fernández, Francisco Javier and Pérez de Pedro, Iván and Gil Morillas, Alba and Navarrete Navarrete, Nuria and Callejas Rubio, José Luis and Ayala Gutiérrez, María Del Mar and Romero Gómez, Carlos and León Ruíz, Laura and Gómiz Rodríguez, Gema and Borrachero Garro, Cristina and Vílchez Parras, Ascensión and Colodro Ruiz, Agustín},
  title = {Efectividad temprana de anifrolumab en lupus eritematoso sistémico: datos de vida real a 3 y 6 meses del registro RALESA},
  journal = {Medicina Clínica},
  year = {2026},
  volume = {166},
  number = {6},
  pages = {107429},
  doi = {10.1016/j.medcli.2026.107429}
}
Kostenlos starten →